Fukuda Denshi Co. Ltd is a world leader in the patient monitoring market and has a license agreement with Senzime since 2016. The agreement grants Fukuda Denshi exclusive rights to license and commercialize Senzime's TetraGraph technology under its own brand at the Japanese market.

Fukuda Denshi has previously purchased components directly from Senzime’s appointed external suppliers. Since Senzime now has its own manufacturing facility in Uppsala, which is approved by both MDR and FDA, the collaboration with Fukuda has now been expanded to also include manufacturing and delivery of systems. The new agreement will also generate revenue for Senzime on manufactured products, in addition to the previous variable royalty fee based on actual sales in Japan.

"Strategic partnerships with leading global companies is a clear strategy for Senzime and the collaboration with Fukuda Denshi is an example of this. Together, we have the right conditions to increase patient safety for millions of patients in Japan. I am expecting continued success in the collaboration between our companies,” commented Philip Siberg, CEO at Senzime.

In Japan, over 2.7 million major operations are performed annually in approximately 13,500 operating rooms. Senzime's TetraGraph is a system used to monitor patients undergoing anesthesia to guide anesthesiologists in ensuring the correct dose of paralytic drugs and indicate when it is safe for the patient to breathe spontaneously again. The TetraGraph system is based on a proprietary algorithm based on electromyography (EMG) which enables accurate monitoring of a patient’s muscle potential in real time.